Company Filing History:
Years Active: 2025
Title: Michael Mandler: Innovator in Fibrosis Treatment
Introduction
Michael Mandler is a notable inventor based in Lawrenceville, NJ (US). He has made significant contributions to the field of medical research, particularly in the treatment of fibrotic diseases. His innovative work has the potential to impact the lives of many patients suffering from various forms of fibrosis.
Latest Patents
Mandler holds a patent for "1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis." This invention relates to 1H-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The compounds developed by Mandler are inhibitors of TLR9 and are useful in treating, preventing, or slowing fibrotic diseases. These diseases include liver fibrosis, renal fibrosis, biliary fibrosis, pancreatic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), and idiopathic pulmonary fibrosis (IPF). He has 1 patent to his name.
Career Highlights
Michael Mandler is associated with Bristol-Myers Squibb Company, a leading global biopharmaceutical company. His role at the company has allowed him to work on groundbreaking research and development projects aimed at addressing critical health issues.
Collaborations
Due to space constraints, the collaborations section will be omitted.
Conclusion
Michael Mandler's innovative work in developing TLR9 inhibitors represents a significant advancement in the treatment of fibrotic diseases. His contributions to medical research continue to pave the way for new therapeutic options for patients in need.